



## Noxopharm appoints Dr Olivier Laczka as new CEO

### Highlights

- Seamless transition with experienced leader
- Driving force behind Sofra™ technology
- Focus on emerging opportunities

**Sydney, 15 April 2026:** Clinical-stage biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce the appointment of Dr Olivier Laczka as its new Chief Executive Officer with immediate effect.

Previously Chief Scientific Officer – Inflammation, Dr Laczka has been the driving force behind the strategic development of the company's highly promising [Sofra™](#) platform for the past several years, and is an experienced innovation leader in drug development, biopharmaceuticals, biotechnology and diagnostics.

As a longstanding member of the company's leadership team, Dr Laczka's appointment ensures a seamless transition as Noxopharm focuses on the opportunities created by its Sofra technology and builds on the success of the recent HERACLES clinical trial and publication of [groundbreaking research](#) in a high-profile journal.

Noxopharm Chairman Fred Bart said: "Dr Laczka has made a very significant contribution to the development of the Sofra program and is the ideal person to steer the next phase of our growth. He has led our scientific team with genuine vision and energy while forming deep collaborative relationships with our external partners, and we have real confidence in his ability to deliver value for our shareholders."

New Noxopharm CEO Dr Laczka said: "I am honoured to have been entrusted by the Board in this new role, and will take responsibility for building the company in our shareholders' best interests. We have a real opportunity to grow by seizing the opportunities that are opening up for us, and not hesitating to make the right decisions that will take us forward."

### Summary of Material Terms of Dr Laczka's Employment

Commencement Date	15 April 2026
Term	No fixed term. Ongoing until terminated by either party in accordance with the employment contract.
Fixed Remuneration	Fixed Remuneration \$290,000 per annum (plus superannuation at 12% without any contribution limited under the Superannuation Guarantee (Administration Act 1992) and subject to annual review.

Performance Options	Dr Laczka has been offered 2 million options at a strike price at a premium of 25% to the next share placement price, that vest subject to certain performance hurdles. These options expire four years from the grant date.
Notice Period	Either party may terminate the employment by providing three months' notice.

**-ENDS-**

### **About the Sofra technology platform**

Developed from a [breakthrough discovery](#) in the immune system, Sofra comprises a novel class of drugs targeting inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines.

[Sofra technology](#) has potential applications in a wide range of diseases related to the immune system such as rheumatoid arthritis, lupus and diabetes, as well as other diseases like cancer.

The global autoimmune disease therapeutics market was worth US\$163.2 billion in 2024 and is expected to reach US\$219.6 billion by 2035, while the worldwide immuno-oncology market was US\$43 billion in 2023 and is projected to hit US\$284 billion by 2033.

The proprietary platform is based on short nucleic acid sequences, the building blocks of DNA or RNA, known as oligonucleotides. These act on specific immune sensors to regulate inflammation at its source, reducing or stimulating it to control the disease.

Further information and animations: [SOF-SKN](#) / [SOF-VAC](#)

### **About Noxopharm**

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to improve the safety profile of a wide range of mRNA medicines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Sofra™ (inflammation, autoimmunity, mRNA drug enhancement, and oncology) and Chroma™ (oncology).

To learn more, please visit: [noxopharm.com](https://noxopharm.com)

#### **Investor, Corporate & Media enquiries:**

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

#### **Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

For personal use only